2.43

2.41% -0.06

After Hours: 2.47 0.04 +1.65%

Moleculin Biotech Inc (MBRX)

Overview News Price History Financials Discussions Forecast Stock Split

Moleculin Biotech Inc stock is traded at $2.43, with a volume of 109.78K. It is down -2.41% in the last 24 hours and up +0.83% over the past month. Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Previous Close:

$2.49

Open:

$2.47

24h Volume:

109.78K

Relative Volume:

0.63

Market Cap:

$11.99M

Revenue:

Net Income/Loss:

$-23.92M

P/E Ratio:

-0.0965

EPS:

-25.1834

Net Cash Flow:

$-22.74M

1W Performance:

+17.96%

1M Performance:

+0.83%

6M Performance:

-80.24%

1Y Performance:

-90.92%

1-Day Range:

$2.40

$2.52

1-Week Range:

$2.01

$2.52

52-Week Range:

$1.79

$28.61

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name

Moleculin Biotech Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

713-300-5160

Address

5300 MEMORIAL DRIVE, HOUSTON, TX

Employee

Twitter

@moleculinbio

Next Earnings Date

2026-03-20

Latest SEC Filings

MBRX's Discussions on Twitter

Compare MBRX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MBRX Moleculin Biotech Inc	2.43	12.28M	0	-23.92M	-22.74M	-25.18
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-25	Resumed	H.C. Wainwright	Buy
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform

Moleculin Biotech Inc Stock (MBRX) Latest News

Mar 25, 2026

Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn

Mar 25, 2026

Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada

Mar 24, 2026

MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView

Mar 24, 2026

MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView

Mar 24, 2026

MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus

Mar 24, 2026

Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada

Mar 24, 2026

Mar 23, 2026

Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart

Mar 23, 2026

Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus

Mar 23, 2026

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget

Mar 23, 2026

Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - TipRanks

Mar 23, 2026

Moleculin enrolls 45th patient in pivotal AML trial - Investing.com

Mar 23, 2026

Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative

Mar 23, 2026

Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView

Mar 23, 2026

Leukemia drug study reaches key 45-patient mark with results due mid-2026 - Stock Titan

Mar 23, 2026

Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan

Mar 23, 2026

Mar 22, 2026

If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan

Mar 22, 2026

Mar 21, 2026

MBRX SEC FilingsMoleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 21, 2026

Mar 20, 2026

Moleculin Biotech, Inc.: Fundamental Analysis and Financial Ratings | MOL0 | US60855D4088 - marketscreener.com

Mar 20, 2026

Mar 19, 2026

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - The Manila Times

Mar 19, 2026

Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative

Mar 19, 2026

[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan

Mar 19, 2026

Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView

Mar 19, 2026

Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan

Mar 19, 2026

MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill

Mar 19, 2026

Moleculin Biotech 2025 Annual Report: Annamycin Clinical Trials & Pipeline Update - Minichart

Mar 19, 2026

Mar 18, 2026

Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView

Mar 18, 2026

Moleculin Biotech (NASDAQ: MBRX) outlines Annamycin Phase 3 AML strategy - Stock Titan

Mar 18, 2026

Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 18, 2026

Mar 17, 2026

Moleculin to Present at 38th Annual ROTH Conference - The Manila Times

Mar 17, 2026

Moleculin Biotech Inc expected to post a loss of $6.11 a shareEarnings Preview - TradingView

Mar 17, 2026

Moleculin leaders set for March 24 ROTH healthcare investor chat - Stock Titan

Mar 17, 2026

Mar 16, 2026

Net current asset value per share of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView

Mar 16, 2026

Mar 14, 2026

Moleculin Reports Second Quarter 2024 Financial Results and Prov - GuruFocus

Mar 14, 2026

Mar 13, 2026

MBRX Should I Buy - Intellectia AI

Mar 13, 2026

Mar 12, 2026

Moleculin Biotech releases CEO update on leukemia trial By Investing.com - Investing.com India

Mar 12, 2026

Mar 11, 2026

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - The Manila Times

Mar 11, 2026

Moleculin Biotech releases CEO update on leukemia trial - Investing.com

Mar 11, 2026

Mar 09, 2026

Moleculin Biotech (MBRX) seeks vote on 6.37M warrants and name change - Stock Titan

Mar 09, 2026

Form DEF 14A Moleculin Biotech For: 9 March By Investing.com - Investing.com Canada

Mar 09, 2026

Mar 07, 2026

Maxim Group Sticks to Their Buy Rating for Moleculin Biotech (MBRX) - The Globe and Mail

Mar 07, 2026

Mar 06, 2026

Pullback Watch: Will Moleculin Biotech Inc benefit from geopolitical trendsMarket Activity Report & Safe Capital Growth Tips - baoquankhu1.vn

Mar 06, 2026

Mar 03, 2026

Moleculin Announces Closing of up to $16.5 Million Public Offering - Quantisnow

Mar 03, 2026

Mar 01, 2026

Aug Reactions: Will Moleculin Biotech Inc benefit from geopolitical trends2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Mar 01, 2026

Feb 28, 2026

MBRX PE Ratio & Valuation, Is MBRX Overvalued - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Moleculin Biotech (MBRX) seeks OK for 6.37M warrants, $15.3M proceeds - Stock Titan

Feb 27, 2026

Feb 22, 2026

Why Did MBRX Stock Climb 14% Today? - Stocktwits

Feb 22, 2026

Feb 20, 2026